Cargando…

DKK1 as a novel target for myeloma immunotherapy

Novel, potent tumor-associated antigens are needed to improve the efficacy of immunotherapy for myeloma. We demonstrated that active vaccination using the DKK1-DNA vaccine in the myeloma mouse model protected mice from developing myeloma and effectively treated established myeloma. Therefore, DKK1 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Jianfei, Yi, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429585/ https://www.ncbi.nlm.nih.gov/pubmed/22934273 http://dx.doi.org/10.4161/onci.19655

Ejemplares similares

Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma
por: Li, Rong, et al.
Publicado: (2020)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
por: Soriani, Alessandra, et al.
Publicado: (2013)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)

A novel strategy for modulation of MDSC to enhance cancer immunotherapy
por: Ghansah, Tomar
Publicado: (2012)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15
por: Müller, Dafne
Publicado: (2012)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

A novel pathway links telomeres to NK-cell activity: Implications for immunotherapy
por: Cherfils-Vicini, Julien, et al.
Publicado: (2014)

Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
por: Nelson, Peter J, et al.
Publicado: (2013)

Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy
por: Suryawanshi, Amol, et al.
Publicado: (2015)

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
por: Lazear, Eric, et al.
Publicado: (2017)

Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment
por: Schuessler, Andrea, et al.
Publicado: (2014)

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
por: Todaro, Matilde, et al.
Publicado: (2013)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Antagonizing the innate pattern recognition receptor CD204 to improve dendritic cell-targeted cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2012)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Shock block for improved immunotherapy
por: Rao, Aparna, et al.
Publicado: (2012)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies
por: Chen, Lei L., et al.
Publicado: (2012)

Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
por: Lu, Yong, et al.
Publicado: (2013)

Personalizing immunotherapy: Balancing predictability and precision
por: Agur, Zvia, et al.
Publicado: (2012)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
por: Raja, Karthick Raja Muthu, et al.
Publicado: (2013)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

A new approach for cellular immunotherapy of nasopharyngeal carcinoma
por: Smith, Corey, et al.
Publicado: (2012)

RIPK3—a predictive marker for personalized immunotherapy?
por: Smola, Sigrun
Publicado: (2015)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o4vk7jkj4428gqr9as2uv1ksm9